VLP-based Vaccines for Targeting Staphylococcus Aureus β-barrel Toxins

基于 VLP 的针对金黄色葡萄球菌 β 桶毒素的疫苗

基本信息

批准号：
10538909
负责人：
Seth Michael Daly
金额：
$ 19.06万
依托单位：
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-20 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10538909
关键词：
Accident and Emergency department Address Affinity Alpha Particles Amino Acid Sequence Animals Antibiotic Resistance Antibiotics Antibodies Antibody Response Antigens Autoantigens Avidity Binding Blood Body Weight decreased Cells Chemical Agents Cytolysis Development Disease Epitopes Health Hemolysin Human Immune Immune Sera Immune Tolerance Immune response Immunity Immunoglobulin G In Vitro Individual Infection Infection prevention Infectious Skin Diseases Intramuscular Knowledge Lesion Mediating Methicillin Resistance Modeling Morbidity - disease rate Mus Panton-Valentine leukocidin Pathogenesis Patients Peptides Phase III Clinical Trials Publishing Serum Skin Tissue Soft Tissue Infections Staphylococcus aureus Staphylococcus aureus infection Stream Structure Tertiary Protein Structure Testing Toxin Vaccination Vaccine Research Vaccines Virulence Factors Virus-like particle Work adaptive immune response adaptive immunity base commensal bacteria design flexibility host colonization human disease human model human pathogen immune function immunogenicity improved in vivo leukotoxin methicillin resistant Staphylococcus aureus monomer mortality mouse model neutralizing antibody novel strategies pathogen patient population peptide based vaccine pre-clinical prevent recurrent infection vaccine development vaccine efficacy vaccine failure vaccine immunogenicity vaccine strategy ventilator-associated pneumonia virtual

项目摘要

PROJECT SUMMARY: Staphylococcus aureus (SA), including methicillin-resistant (MRSA), is the most common cause of skin and soft tissue infection (SSTI) in the US. SA causes recurrent infections, particularly in highly susceptible patient populations with reduced immune function. To date, no vaccine to prevent SA infection has succeeded in human trials. Meanwhile, the need for a vaccine continues to escalate, as does the ability of this pathogen to acquire antibiotic resistance. We have developed a virus-like particle (VLP)-based vaccine strategy to control SA secreted β-barrel pore-forming toxins. In models of skin infection, a vaccine based on this approach induces antibodies that prevent infection pathogenesis, spares host immune cells and limits disease. In this proposal, we aim to evaluate the preclinical potential of this vaccine strategy against a variety of SA β-barrel pore-forming toxins. We will determine vaccine immunogenicity in vivo, and efficacy in SA colonization. Our results could lay the groundwork for development of an efficacious vaccine to prevent SA infection and limit pathogenesis. This vaccine could significantly improve the health of patients who suffer from SA infections.

项目摘要：金黄色葡萄球菌（SA），包括耐甲氧西林的（MRSA）为在美国，皮肤和软组织感染（SSTI）的最常见原因。 SA会反复出现感染，特别是在高度易感的患者种群中，免疫功能降低。到日期，没有预防SA感染的疫苗在人类试验中取得了成功。刻薄的是，需要疫苗继续升级，这种病原体获得抗生素的能力也是如此反抗。我们已经开发了类似病毒的颗粒（VLP）的疫苗策略来控制SA 分泌的β-桶孔形成毒素。在皮肤感染模型中，基于此的疫苗方法诱导防止感染发病机理的抗体，备件宿主免疫细胞和限制疾病。在此提案中，我们旨在评估该疫苗策略的临床前潜能针对各种SAβ-桶孔形成的毒素。我们将确定疫苗免疫原性体内和SA定植的效率。我们的结果可能为开发的基础奠定了基础一种有效的疫苗，可防止SA感染并限制发病机理。这种疫苗可以显着改善患有SA感染的患者的健康状况。